2022 Year in Review: Launching a New Era of Innovation
2022 Storytelling Highlights
Leah's ALS Story
Leah shares her experience being diagnosed and living with ALS. Through Gateway Labs by Lilly, our shared innovation accelerator, we're hoping to facilitate the scientific breakthroughs that will lead to cures for people like Leah—who urgently need them.
Additional Resources
Lilly Cautionary Statement Regarding Forward-Looking Statements
The statements made in the 2022 Year in Review contain forward-looking statements that are based on management’s current expectations, but actual results may differ materially due to various factors. Words such as “estimate”, “project”, “intend”, “expect”, “believe”, “target”, “anticipate” and similar expressions are intended to identify forward-looking statements. The company's sustainability targets, goals, and commitments, as well as its operating results, business goals, strategy, and development or launch of any medicine may be affected by factors including, but not limited to, the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; the impact and outcome of acquisitions and business development transactions and related integration costs; the expiration or enforceability of intellectual property protection for certain of our products; changes in patent law or regulations; competitive developments affecting current products and our pipeline; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data in our information technology systems, networks, and facilities, or those of third parties with whom we share our data; the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally; unexpected safety or efficacy concerns associated with our products; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities; issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, or regulatory actions related to our facilities; the impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic; and changes or other developments in laws or regulations.
For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements except as required by applicable law.
Find more detail on Lilly’s environmental, social and governance priorities, strategies and operations at esg.lilly.com.